Since its establishment in 1982, Shantou Institute of Ultrasonic Instruments Co., Ltd. (SIUI) has been committed to the innovative development of human safety and health, unswervingly dedicated to the research, development and manufacturing of medical imaging instruments and non-destructive testing equipment. It has continuously made significant breakthroughs in various fields and achieved stable and rapid development. Nowadays, SIUI has become a national key high-tech enterprise integrating research and development, manufacturing, and sales of medical ultrasound system, portable DR system, industrial ultrasound instrument, and intelligent service platforms. Advanced technology, high-end equipment, exquisite craftsmanship, high-quality products, and comprehensive services have earned SIUI a high level of trust among industry professionals. As a leading high-tech enterprise in the nation, SIUI has consistently invested in technological innovation for many years, achieving numerous high-tech breakthroughs and successfully commercializing them, enabling SIUI’s products to perform even better. SIUI will base on the technology of ultrasound and diversify its development in the fields of medical imaging systems and nondestructive testing equipment.
Serilink Biotechnology Company Limited
Serilink is a startup specializing in the research and development of XDC and peptide drugs . It builds a targeted drug development pipeline from medicinal chemistry to IND through collaboration and independent research . Serilink focuses on the development of conjugated nuclear medicine (ARCs or RDCs), antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), PEGlyation drugs, and protein-conjugated polysaccharide vaccines. We develop structurally innovative and performance-enhanced conjugated drug candidate compounds, empowering and providing new molecular drugs and development platform technologies to pharmaceutical companies in need of transformation and innovation. | Serilink Biotechnology Company Limited (“Serilink”) specializes in peptide/protein drug synthesis, modification, and bioconjugations using novel technologies. Its primary focus is on the development of antibody/peptide drug conjugates (ADCs, ARCs, PDCs, collectively referred to as XDCs). Serilink collaborates with partners to co-develop drugs, aiming at advancing them to the PCC or further to IND stage. Established in 2022, Serilink has successfully relocated to the government-funded Incu-Bio facility in Hong Kong Science Park. Our main expertise: Organic synthesis of small molecules Pharmaceutical chemistry synthesis and repair of peptide / protein drugs Conjugation between small molecules and biological macromolecules (covalent connections) Polypeptide drug conjugation Chemical biology and Cell biology
SeqOne
SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under HIPAA as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. | SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.
SensID, a Microbiologics Company
“Microbiologics helps cancer researchers and diagnostic developers trust every result with high-quality reference materials from our SensID portfolio. SensID products are designed to reflect real clinical samples and support assay development, validation, and ongoing quality control across molecular oncology testing. Our portfolio spans key material types, including: human genomic DNA (gDNA) controls, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) for liquid biopsy assays, human-tech plasma for full workflow controls, and formalin-fixed paraffin-embedded (FFPE) standards for solid tumor applications. Well-known examples include EGFR-Multiplex cfDNA sets for mutation detection across allele frequencies, ESR1 & PIK3CA reference sets for precision liquid biopsy quality control, and MSI/MSS FFPE reference materials to mimic patient samples in microsatellite instability testing. Researchers use SensID products to validate NGS and PCR assays, benchmark instrument performance, and monitor routine operations with confidence. Backed by deep genomic characterization and consistent lot performance, SensID materials help you advance oncology workflows with clarity and reliability.”
Seno Medical Instruments Inc
Seno Medical’s imaging system uses opto-acoustic technology fused with ultrasound (OA/US) to generate functional and anatomical images of the breast. As a new imaging modality, Seno has proven at a fixed sensitivity of 98% that its Imagio® breast imaging system is a more effective tool to help radiologists confirm or rule out malignancies than current diagnostic ultrasound imaging approaches, without exposing patients to potentially harmful ionizing radiation (X-rays) or contrast agents.
Select Friuli Venezia Giulia
Select Friuli Venezia Giulia is the regional investment development agency supporting foreign direct investment in Friuli Venezia Giulia (FVG), a dynamic region in northeastern Italy at the crossroads of Central and Eastern Europe. We provide tailored support to international investors throughout every stage of their investment journey: from identifying business opportunities and accessing incentives, to establishing local contacts and navigating the regional ecosystem. FVG offers a unique economic and industrial system, featuring: • Competitive, innovation-driven companies • Advanced infrastructure and logistics • Strong, export-oriented manufacturing and production clusters • A business-friendly environment with attractive incentives and streamlined procedures With its strategic location, skilled workforce, and international outlook, Friuli Venezia Giulia is the ideal gateway to Europe for global businesses. | Friuli Venezia Giulia, Italy’s first Strong Innovator region, offers a dynamic R&D ecosystem with tech firms, universities, labs and incubators. A strategic European logistics hub, it’s ideal for AI, quantum and new tech projects. Select Friuli Venezia Giulia Agency supports investors at every stage.
Sedecal USA Inc
Creating your X-Ray Vision. Discover Turnkey Innovative radiographic OEM Solutions Incorporate cutting-edge technology at your center/s with SEDECAL S.A. 1. Your One-Stop OEM Partner From design to validation, certification, production, and support — Cut cost, we handle. 2. Tailored to your customs needs i) Find configurable systems adapted to your needs, from top to basics — Smarter spending. 3. Comprehensive X-Ray Imaging Portfolio Battery compact and powerful Generators, fixed/digital RAD & RF rooms, digital/analogue mobile systems, surgical C-arms and the state of art software — Full range, less hassle. 4. Cutting-Edge Technology i) Explore new techniques like tomosynthesis, dual energy, automatic stitching and DSA — Improve lesion detections. 5. Advanced Diagnose Solution a) AI chest powered and virtual collimation – Earlier and more accurate diagnosis. 6. Fit for Every Imaging Site From entry-level rooms to high-end installations, we covered your specific demands. 7. Flexibility of Software/detector Integration Ready to be integrated with virtually any X-Ray detector and imaging software – Keep cost lean. 8. Built-In Quality at Every Step Strict quality protocols from design to after-sales, aligned with EU and US standards. 9. Future is here. Find what new Patients demand and healthcare Center must deliver SEDECAL S.A. – Your Strategic OEM Partner. Shaping your ideas. Sedecal will do the rest. You are not alone. | Creating your X-Ray Vision. Discover Turnkey Innovative radiographic OEM Solutions Incorporate cutting-edge technology at your center/s with SEDECAL S.A. 1. Your One-Stop OEM Partner 2. Tailored to your customs needs 3. Comprehensive X-Ray Imaging Portfolio 4. Cutting-Edge Technology 5. Advanced Diagnose Solution 6. Fit for Every Imaging Site 7. Flexibility of Software/detector Integration 8. Built-In Quality at Every Step 9. Future is here. Find what new Patients demand and healthcare Center must deliver. SEDECAL S.A. Your Strategic OEM Partner. Stand nº4340 Shaping your ideas. Sedecal do the rest. You are not alone